Cintia Piccina Insider Profile
4 Followers
Cintia Piccina, U.S. CCO & Country Gen Manager at Autolus Therapeutics, holds 13.29K shares in Autolus Therapeutics (Ticker: AUTL), holds 18.42K shares in Adaptimmune Therapeutics (Ticker: ADAPY), holds 147.00K shares in Kalaris Therapeutics (Ticker: KLRS).
Cintia Piccina has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Cintia Piccina holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Cintia Piccina
Cintia Piccina's Trading History
Autolus Therapeutics
Sep 03, 2026
U.S. CCO & Country Gen Manager
Uninformative Buy
47.00K
$26.04K
Adaptimmune Therapeutics
Jan 15, 2025
CCO
Uninformative Sell
7.40K
$423.68
Kalaris Therapeutics
Jul 05, 2023
Chief Commercial Officer
Uninformative Buy
―
$485.10K
List of latest transactions for each holding click on a transaction to see Cintia Piccina's performance on stock
You May Also Like
Cintia Piccina insider profile FAQ
What is the percentage of profitable transactions made by Cintia Piccina?
The percentage of profitable transactions made by Cintia Piccina is ―.
What is the average return per transaction made by Cintia Piccina?
The average return per transaction made by Cintia Piccina is ―.
What stocks does Cintia Piccina hold?
Cintia Piccina holds: AUTL, ADAPY, KLRS stocks.
What was Cintia Piccina’s latest transaction?
Cintia Piccina latest transaction was an Uninformative Buy of $47.00K.
What was Cintia Piccina's most profitable transaction?
Cintia Piccina’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Cintia Piccina's role in Autolus Therapeutics?
Cintia Piccina's role in Autolus Therapeutics is U.S. CCO & Country Gen Manager.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.